References
- Chia PL , MitchellP, DobrovicA, JohnT. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin. Epidemiol.6, 423 (2014).
- Zhou W , ChristianiDC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin. J. Cancer.30(5), 287 (2011).
- Carlson JJ , SuhK, OrfanosP, WongWJP. Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Clin. Drug Investig.36(4), 495–504 (2018).
- Awad MM , ShawAT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin. Adv. Hematol. Oncol.12(7), 429–439 (2014).
- Shaw AT , YeapBY, Mino-KenudsonMet al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol.27(26), 4247 (2009).
- Doebele RC , PillingAB, AisnerDLet al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res.18(5), 1472–1482 (2012).
- Sawada S , SuehisaH, UenoTet al. Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography. Lung Cancer (Auckl).7, 45–51 (2016).
- Choi SH , KimYT, KimSKet al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann. Thorac. Surg.92(5), 1826–1832 (2011).
- Chia PL , MitchellP, DobrovicA, JohnTJCE. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin. Epidemiol.6, 423 (2014).
- Younes RN , GrossJL, DeheinzelinDJC. Follow-up in lung cancer: how often and for what purpose?115(6), 1494–1499 (1999).
- Ilié M , HofmanP. Pros:can tissue biopsy be replaced by liquid biopsy?Transl. Lung Cancer Res.5(4), 420 (2016).
- Alix-Panabières C , PantelK. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov.6(5), 479–491 (2016).
- Pantel K , Alix-PanabieresC. Liquid biopsy: Potential and challenges. Mol. Oncol.10(3), 371–373 (2016).
- Pailler E , AdamJ, BarthelemyAet al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J. Clin. Oncol.31(18), 2273–2281 (2013).
- He W , XuD, WangZet al. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma. J. Transl. Med.17(1), 32 (2019).
- Pailler E , OulhenM, BorgetIet al. Circulating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK-rearranged non-small cell lung cancer patients. Cancer Res.77(9), 2222–2230 (2017).
- Imamura F , UchidaJ, KukitaYet al. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer94, 68–73 (2016).
- Chabon JJ , SimmonsAD, LovejoyAFet al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun.7(1), 1–15 (2016).
- Tan CL , LimTH, LimTKet al. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. Oncotarget7(17), 23251 (2016).
- Zhang Z , ShiratsuchiH, PalanisamyNet al. Expanded circulating tumor cells from a patient with ALK-positive lung cancer present with EML4-ALK rearrangement along with resistance mutation and enable drug sensitivity testing: a case study. J. Thorac. Oncol.12(2), 397–402 (2017).
- Kidess-Sigal E , LiuHE, TribouletMMet al. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget7(51), 85349 (2016).
- Moreno JG , O’HaraSM, GrossSet al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology58(3), 386–392 (2001).
- Hartkopf AD , WagnerP, WallwienerDet al. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res.31(3), 979–984 (2011).
- Tan K , LeongSM, KeeZet al. Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients. Cancer Lett.423, 1–8 (2018).
- Yang B , QinA, ZhangKet al. Circulating tumor cells predict prognosis following tyrosine kinase inhibitor treatment in EGFR-mutant non-small cell lung cancer patients. Oncol. Res.25(9), 1601–1606 (2017).
- Tong B , XuY, ZhaoJet al. Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer. Thorac. Cancer9(5), 640–645 (2018).
- Lee Y , ParkS, KimWSet al. Correlation between progression–free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced–stage EGFR–mutated non–small cell lung cancer. Thorac. Cancer9(9), 1104–1110 (2018).